To overcome gene therapy barriers such as low transfection efficiency and nonspecific delivery, liposomal nanoparticles targeted by a single-chain antibody fragment to the transferrin receptor (TfRscFv) delivering wild-type (wt) human p53 (SGT-53) were developed for tumor-specific targeting. We hypothesize that SGT-53 in combination with gemcitabine will demonstrate enhanced therapeutic benefit in an in vivo metastatic pancreatic cancer model. Intrasplenic injection of 1 Â 10 6 Panc02 murine pancreatic cancer cells was used to generate in vivo hepatic metastatic tumors. Nanoparticle localization was assessed by tail vein injection of TfRscFv with fluorescently labeled oligonucleotides (6-carboxyfluorescein phosphoramidite (6FAM) ODN) imaged by Xenogen IVIS 200 scan. SGT-53 (equivalent to 30 mg of p53 intravenously) and gemcitabine (20 mg/kg intraperitoneally) alone and in combination were administered biweekly and compared with untreated mice. Survival was determined by blinded daily assessment of morbidity. Human wtp53 expression and transferrin levels in the tumors were assessed by western blot analysis. Tumor burden was quantified by liver weight. Xenogen imaging demonstrated tumor-specific uptake of TfRscFv-6FAM ODN. Exogenous human wtp53 protein was detected in the SGT-53-treated tumors compared with control. Compared with untreated mice with metastatic tumors demonstrating median survival of 20 days, SGT-53, gemcitabine and the combination demonstrated improved median survival of 29, 30 and 37 days, respectively. The combination treatment prolonged median survival when compared with single drug treatment and decreased tumor burden. The tumor targeting liposomal-based SGT-53 nanoparticle is capable of sensitizing pancreatic cancer to conventional chemotherapy in pancreatic cancer models. This approach has the potential to be translated into a new, more effective therapy for pancreatic cancer. Further optimization is ongoing, moving towards a Phase 1B/2 clinical trial.
INTRODUCTION
With nearly 44 000 estimated new cases with 37 000 estimated deaths in 2012, pancreatic adenocarcinoma remains the fourth leading cause of cancer-related deaths in the United States, highlighting the devastating nature of this malignancy. 1 Over the past few decades, mortality from breast, colon, lung and prostate cancer has steadily decreased. Conversely, mortality from pancreas cancer has remained relatively stable since the 1950s owing to the lack of significant progress in the fight against pancreatic cancer. Even with optimal surgery and aggressive adjuvant therapy, overall survival from pancreatic cancer remains poor with reported 5-year survival rates of only 15-20%. 2 Although surgery is the only curative option, o20% of patients are eligible for surgery owing to metastatic spread at the time of diagnosis. 3 Pancreatic cancer patients with metastatic spread at diagnosis have a dismal survival of o9 months. 4 Gemcitabine chemotherapy remains a primary option for patients with metastatic pancreatic cancer. 3, 5 However, gemcitabine only prolongs survival approximately 6 months, nearly 2 months longer than 5-fluorouracil in multiple Phase III clinical trials and only extended 1 year survival to 18%. 6, 7 The exceedingly poor prognosis for patients with pancreatic cancer necessitates further development of novel therapeutic approaches incorporating gene therapy strategies.
Critical hurdles still exist preventing effective gene therapy in vivo and, more importantly, in the clinic. These include low transfection efficiency, poor tissue penetrance as well as nonspecific delivery. 8 To overcome these barriers, many strategies have been developed, such as viral, liposome and polyethyleneimine delivery mechanisms. However, these strategies are primarily non-targeted, resulting in poor efficiency and significant nonspecific gene silencing. 8 Viral delivery strategies have improved transfection efficiency, although they lack specific targeting and the viral particles can have residual immunologic effects. Cationic liposomes composed of positively charged lipid bilayers can be used to delivery gene therapy, but similarly lack specificity.
Specific targeted vector strategies are appealing to improve delivery directly and more efficiently to the tumor. The transferrin (Tf) receptor has been investigated as a potential target for vector delivery in gene therapy with growing support. 9 In pancreatic cancer, the Tf receptor was overexpressed in 93% of the pancreatic tumor cells relative to normal tissue, suggesting that it may be a specific marker for malignancy. 10 A second factor supporting the Tf receptor as an appropriate target in pancreatic cancer is that the Tf receptor is recycled during internalization in rapidly dividing cancer cells, thus improving uptake of Tf-targeted vectors. 8 Recently, a nanoparticle liposome-based complex targeting the Tf receptor has been used to target specifically tumors for gene therapy. 8, [11] [12] [13] [14] [15] In this complex, the payload is encapsulated within a cationic liposome, the surface of which is decorated with an antiTf receptor single-chain antibody fragment (TfRscFv) targeting moiety. When systemically administered, this self-assembled, biodegradable, nanosized complex has been shown to preferentially target and efficiently deliver gene therapies, not only to primary tumors but also to metastatic lesions (including in the brain) in animal models, delivering plasmid DNA carrying normal human p53 gene, 14, 15 antisense HER-2, 16 chemotherapeutic agents, 17 small interfering RNAs, 11 and magnetic resonance imaging contrast agents, gadolinium 12, 18 and superparamagnetic iron oxide. 19, 20 Although taken up by cells of the reticuloendothelial system of the liver and lung, as it is not a sterically stabilized particle, this nanocomplex does not transfect the hepatocytes or lung aveolar cells themselves. 8, 11, 12, 19 p53 restoration has been shown most effective in enhancing cytotoxicity when used in combination with an agent that results in DNA damage or initiates apoptosis. 21, 22 Given the proapoptotic and antineoplastic effects of p53 restoration therapy, we hypothesized that SGT-53 treatment should increase the responsiveness of pancreatic cancer tumor cells to gemcitabine and, therefore, enhance gemcitabine therapy in a metastatic pancreatic cancer model.
MATERIALS AND METHODS

Cell lines and culture conditions
Murine Panc02 cells were obtained from the NCI DCTD Tumor Repository (NCI, Frederick, MD, USA). Panc02 murine pancreatic cancer cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum. Human pancreatic adenocarcinoma AsPC-1, BxPC-3, Capan-2, HPAC, MIA PaCa-2 and PANC-1 were maintained in RPMI 1640 (AsPC-1, BxPC-3 and Capan-2) or Dulbecco's modified Eagle's medium (HPAC, MIA PaCa-2 and PANC-1) supplemented with 10% fetal bovine serum. Mycoplasmanegative cultures were ensured by polymerase chain reaction testing using MycoSensor PCR assay kit (Agilent Technologies, La Jolla, CA, USA) before the investigations. Cells were monitored throughout the course of these studies and demonstrated consistent morphology and doubling time.
Reagents
TfRscFv-Lip carrying a 6-carboxyfluorescein phosphoramidite (6FAM)-labeled phosphorothioate, non-sequence-specific, scrambled (5 0 -6FAM-CTAGCCATGCTTGTC-3 0 ) oligonucleotides (6FAM-ODN) (TriLink Biotechnologies, San Diego, CA, USA) and TfRscFv-Lip-p53 (SGT-53) were prepared as described previously. 15, 16, 23 Briefly, the cationic lipid consisted of a 1:1 molar ratio of dioleoyltrimethylammonium propane and the fusogenic neutral lipid dioleolyphosphatidylethanolamine prepared by the ethanol injection method. 24 Cytomegalovirus promoter controlled plasmid containing the wild-type (wt) p53 was used to deliver the gene therapy. The complex is prepared by simple mixing of the components at a defined ratio in a specific order. 23 Previously, the SGT-53 particle was optimized with DNA/lipid ratio of 1:14 mg nmol À 1 and TfRscFv protein/lipid ratio of 20 mg mmol À 1 . The SGT-53 immunolipoplex particle has a size o400 nm (number average) as measured on a Malvern Nano ZS (Malvern Instruments, Malvern, UK) with a net positive charge between 20 and 40 mV. 19 The immunolipoplex preparations were lyophilized and stored at À 20 1C. For injection, the samples were reconstituted by the addition of the appropriate volume of phosphate-buffered saline (PBS).
Goat anti-rabbit and horse anti-mouse horseradish peroxidaseconjugated antibodies were acquired from Cell Signaling Technology (Danvers, MA, USA). Mouse monoclonal antibody against Tf receptor was obtained from Life Technologies (Grand Island, NY, USA). Mouse monoclonal antibody against p53 (DO-7) was obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Rabbit polyclonal antibody against b-actin was obtained from Sigma (St Louis, MO, USA).
Western blot analysis
Cultured cells were suspended in radioimmunoprecipitation assay protein lysis buffer (pH 7.4), containing 20 mM sodium phosphate, 150 mM sodium chloride, 1% Triton X-100, 5 mM ethylenediaminetetraacetic acid, 5 mM phenylmethylsulfonyl fluoride, 1% aprotinin, 1 mg ml leupeptin and 500 mM Na 3 VO 4 . Tumor sections were dissected and homogenized in icecold radioimmunoprecipitation assay buffer (3 ml radioimmunoprecipitation assay buffer per g wet tissue). After 30 min incubation on ice, tissue debris was removed by centrifugation at 10 000 g for 10 min at 4 1C. Protein concentration was quantified using Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). In all, 20 mg of total protein from cultured cells or 200 mg of tissue extracts was resolved with sodium dodecyl sulfate polyacrylamide gel electrophoresis (10% polyacrylamide gel), and transferred to Amersham Hybon-ECL membrane (GE Healthcare, Piscataway, NJ, USA). Blots were probed with mouse monoclonal antibodies against p53 (1:200 dilution) or Tf receptor (1:500 dilution) in 5% non-fat milk at 4 1C for 16 h. All membranes were stripped and reprobed with b-actin antibody for loading control. Membranes were developed using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific).
Flow cytometry
Single-cell suspensions of murine Panc02 cells were stained with phycoerythrin-conjugated anti-CD71 (Tf receptor) antibody. Live-gated cells were analyzed with the FlowJo software (Treestar, Ashland, OR, USA) for CD71 expression compared with unstained controls.
Cell growth assay
For the in vitro proliferation assays, Panc02 cells were seeded in flatbottom, 96-well plates (2000 cells per well) in RPMI 1640 plus 10% fetal bovine serum. After 24 h, the cells were treated with 50 ml of serum-free medium containing SGT-53 (equivalent to 100 ng p53). After 4 h incubation, 100 ml of RPMI 1640 plus 10% fetal bovine serum containing 0, 0.2 and 0.5 mM gemcitabine was added to each well. At 72 h posttreatment, 10 ml of a 1-(4,5-dimethythiazol-2-yl)-3,5-diphenyltetrazolium bromide dye solution (5 mg ml; Sigma, St Louis, MO, USA) was added to each well, and the plate was incubated at 37 1C for 4 h. Reactions were stopped by the addition of 100 ml of a 10% sodium dodecyl sulfate/ 0.01 M HCl solution. After an additional overnight incubation, absorbance at 570-630 nm was recorded on a BioTek microtiter plate reader (Winooski, VT, USA).
In vivo metastatic pancreatic cancer model C57BL/6 mice (8-12 weeks old) were used for these experiments, which were performed according to protocols approved by the Institutional Animal Care and Use Committee at the Medical University of South Carolina. This model has been previously described in detail. 25 Briefly, following anesthesia, 1 Â 10 6 Panc02 cells in 0.1 ml PBS (Hyclone, Logan, UT) were injected using a 28-G needle and syringe directly into the tip of the exteriorized spleen through a 1 cm left subcostal incision. Animals were monitored daily for health, and moribundity was determined by a blinded investigator. Untreated mice become moribund at an average of 18-20 days after tumor injection. In all cases, animals were killed if evidence of pain or suffering was present.
Assessment of nanoparticle tumor targeting
TfRscFv-Lip-6FAM-ODN particle was assessed for tumor localization based on Xenogen imaging. Mice with advanced tumors were either tail vein injected with TfRscFv-Lip-6FAM-ODN or PBS (Hyclone) on day 14 after intrasplenic cancer cell injection with imaging performed 12 h later. Fluorescence of the liver and spleen was captured on CCD camera (excitation 445-490 nm/emission 515-575 nm) and analyzed.
Treatment schedule
For therapeutic assessment of TfRscFv-Lip-p53 (SGT-53) in combination with gemcitabine, we used a 20 mg/kg intraperitoneally gemcitabine dose delivered two times weekly. 25 SGT-53 (370 ml suspended in PBS, equivalent to 30 mg of p53) was administered via tail vein injection two times weekly. This treatment schedule was based on the previously determined timing of the expression of the exogenous p53 in mouse tumor models. 26 Gemcitabine administration was initiated at 48 h after SGT-53 treatment. Both SGT-53 and gemcitabine treatments continued for 4 weeks.
In vivo therapeutic end points
Two independent in vivo studies using the metastatic pancreatic cancer model were performed to assess the efficacy of the Tf receptor-targeted p53 gene therapy combined with gemcitabine. In the first experiment, SGT-53 treatment was initiated on day 5 after tumor implantation. In total, 7 mice were used in each treatment group except the combination group with 10 mice. Mice were treated for 4 weeks and then observed. Mice were closely followed and humanely killed when morbidity was determined by an investigator in a blinded manner. In a parallel tumor quantitative experiment, SGT-53 treatment was initiated on day 8 after tumor implantation. We terminated the experiment on day 19 after killing all the experimental mice at the same time point for molecular and quantitative tumor analysis.
Immunohistochemistry
Tumors were fixed in 10% buffered formalin, set in paraffin blocks and processed into 5-mm-thick sections. Sections were stained with standard hematoxylin and eosin. Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) was performed according to the manufacturer's directions (DeadEnd Colorimetric TUNEL System; Promega, Madison, WI, USA). TUNEL-positive cells were quantified at Â 400 magnification, with three random fields counted per section. Antigen retrieval was performed before Ki-67 staining by immersing the slides in 10 mM citrate buffer (pH 6.0, Antigen Unmasking Solution; Vector Labs, Burlingame, CA, USA) and microwaving for 10 min. Sections were stained with anti-Ki-67 antibody (Abcam, Cambridge, MA; no. 15580) overnight at 1:750 dilution. Secondary antibody and DAB chromogen detection was performed following the manufacturer's protocol (Rabbit IgG Vectastain Elite ABC kit; Vector Labs). Ki-67-positive cells were counted at Â 400 magnification, with at least three random fields counted per section.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism 5 software (La Jolla, CA, USA). Kaplan-Meier survival analysis was used for the metastatic morbidity study. Linear regression analysis was used to identify correlations between bioluminescence total flux and tumor weight, with a P-value o0.05 considered statistically significant for identifying the existence of a relationship and a goodness-of-fit R 2 value to determine the extent of said relationship. Two-tailed unpaired Student's t-tests were used for statistical analysis in all other experiments, with a P-value o0.05 considered statistically significant. In vitro efficacy of SGT-53 in combination with gemcitabine Compared with untreated control group, SGT-53 treatment alone had no effect on the growth of Panc02 cells. Gemcitabine treatment (0.5 mM) demonstrated 19% decrease in growth. The combination of SGT-53 and 0.5 mM gemcitabine inhibited cell growth by 49% (Figure 2 ; Po0.001 vs control, SGT-53 alone and 0.5 mM gemcitabine alone). Gemcitabine (0.2 mM) did not significantly decrease cellular growth. However, the addition of SGT-53 with 0.2 mM gemcitabine inhibited growth by 35% (Figure 2 ; Po0.01 vs control, SGT-53 alone and 0.5 mM gemcitabine alone). Prior investigations have established the cancer cell targeting ability and specificity of this TfRscFv complex. Previously performed in vitro competition studies with the addition of free TfRscFv effectively inhibited the transfection activity of TfRscFv complexed nanoparticles. The observed effect was dose-dependent, suggesting that the demonstrated transfection efficiency is mediated through targeting the Tf receptor. 14, 15, 27 Tumor localizing ability of the TfRscFv-LipA nanoparticle to hepatic metastatic pancreatic cancer tumors In our metastatic pancreatic cancer model, we assessed tumor targeting of the TfRscFv-Lip-6FAM ODN. Tumor targeting was assessed at a late tumor growth time point (14 days after splenic injection) to determine tumor penetration at an advanced tumor stage. On the basis of ex vivo organ Xenogen IVIS 200 imaging 12 h after tail vein injection of TfRscFv-Lip-6FAM ODN particle compared with saline control, a significant increase in signaling intensity was observed both in the tumor-bearing liver and splenic tissue (Figure 3a) . Fluorescence intensity analysis demonstrated a 43-fold increase intensity in the tumor bearing tissues injected with TfRscFv-Lip-6FAM ODN compared with control (Figures 3b  and c) . This result demonstrates the tumor-specific targeting ability of the TfRscFv-Lip nanoparticle in our metastatic pancreatic cancer model. Previously performed in vivo experiments also incorporated a control single-chain antibody fragment (which does not target the Tf receptor), as the targeting moiety demonstrating no tumor-targeting specificity compared with the TfRscFv complexed nanoparticles, suggesting that the tumortargeting ability is specific to the TfR antibody fragment.
RESULTS
Expression of
14
In vivo efficacy of SGT-53 in combination with gemcitabine in a metastatic pancreatic cancer model We assessed the efficacy in two separate in vivo experiments using the described metastatic pancreatic cancer model. TfRscFvLipA without p53 has previously shown no efficacy relative to untreated control. 28 Therefore, for these experiments, PBS was used as a control group. In the first experiment, we assessed longterm survival based on mouse morbidity. Treatment was continued for a total of 4 weeks and then the mice were observed for signs of morbidity. In a second experiment using the same in vivo model, all treatments groups were killed at the same time point 19 days following tumor implantation. This was performed to compare treatment group in regards to p53 expression and to assess the effect of treatment on tumor burden (liver weight).
In the survival experiment, SGT-53 combined with gemcitabine significantly extended the time to observed morbidity. of morbidity while on treatment. However, after 4 weeks, once treatment was discontinued, the mice rapidly demonstrated significant morbidity related to tumor progression, suggesting that the treatment effectively suppressed growth in this aggressive metastatic pancreatic cancer model. In the second experiment, all groups were terminated on day 19 after tumor implantation when control mice demonstrated signs of increasing morbidity to allow for comparison of tumor burden and for tumor molecular analysis. To demonstrate SGT-53 delivery, we assessed exogenous human-specific p53 protein expression by western blot analysis. Compared with untreated and gemcitabinetreated tumors, SGT-53-treated tumors demonstrated exogenous human p53 expression (Figure 5a ). The presence of exogenous human p53 demonstrates successful delivery of the SGT-53 complex. Owing to the efficacy of the combination treatment in which no significant tumor burden was evident on day 19, this group could not be assessed for the presence of exogenous p53.
Liver weight in grams (g) was significantly increased in the untreated tumor-bearing mice (2.68±0.27 g) compared with normal mouse liver (without tumor; 1.16±0.08 g) (Po0.05). Average liver weight in the SGT-53 (2.22 ± 0.52 g), gemcitabine alone (2.14 ± 0.28 g) and in the combination treatment group (SGT-53/gemcitabine; 1.61±0.12 g) were decreased compared with untreated control. (Figure 5b ). The combination group demonstrated the lowest tumor burden compared with the other groups based on liver weight (Po0.05).
TUNEL staining demonstrated significantly increased tumor cell apoptosis in the combination treatment group. No significant differences were observed in the untreated, gemcitabine and SGT-53 treatment groups, with an average of 5, 5 and 8 apoptotic cells per high-power field identified, respectively (Figures 5c and d) . However, in the combination group, 22 apoptotic cells per highpower field were identified, suggesting an increase in apoptosis compared with the other groups possibly explaining the observed differences in liver tumor burden (Po0.001). No differences were noted in proliferation based on Ki-67 staining (data not shown).
DISCUSSION
The exceedingly poor prognosis for patients with pancreatic cancer necessitates further development of novel therapeutic approaches, including novel gene therapy strategies. To overcome barriers preventing effective gene therapy, a liposome-based nanocomplex targeting the Tf receptor using an anti-Tf receptor single-chain antibody fragment (TfRscFv-Lip) have been used to target tumors specifically. 8, 13, 14, 26, 28, 29 This promising strategy has demonstrated effectiveness delivering p53 therapy (SGT-53) in various preclinical cancer models. 14, 26, 28, 29 Previously published results using this nanodelivery system have demonstrated its in vivo targeting specificity in delivering 6FAM-ODN to breast cancer metastatic lesions in the lungs in which only the tumor nodule displayed a high level of fluorescence with no significant signal in the adjacent normal lung tissue. 11 Similarly, in an investigation using an orthotopic prostate cancer model, systemically delivered TfRscFv-Lip-6FAM-ODN was visualized by fluorescence signal only in the primary tumor without uptake in the normal liver. 8 In vivo studies incorporating a control singlechain antibody fragment failed to demonstrate tumor targeting compared with the TfRscFv-Lip nanoparticle. These previous in vivo experiments along with previously performed in vitro competition studies using free TfRscFv demonstrate compelling evidence that the targeting ability of the TfRscFv-Lip nanoparticle is specifically mediated through the Tf receptor. The current investigation demonstrates that the nanocomplexbased p53 gene therapy can enhance gemcitabine efficacy in an immunocompetent metastatic pancreatic cancer model. The combined therapy extended mouse survival, decreased tumor burden and increased tumor cell apoptosis. Furthermore, we demonstrated enhanced tumor expression of human p53 protein by western blot analysis confirming effective gene therapy delivery. Tumor localization of the TfRscFv-LipA particles was demonstrated based on Xenogen imaging of the 6FAM-ODN particle.
Our results highlight the clinical potential of molecular-based tumor targeting nanoparticles as gene therapy vehicles as well as the therapeutic benefit of p53 gene therapy to enhance current chemotherapy efficacy. Given the effectiveness of p53 restoration in enhancing cytotoxicity when used in combination with an agent, which results in DNA damage or initiates apoptosis, we hypothesized that SGT-53 would increase the efficacy of gemcitabine. 21, 22 Although the combination of gemcitabine with SGT-53 extended survival significantly compared with untreated and individual treatment groups, the difference was much less than that observed in prior investigations using SGT-53. The aggressive tumor model used in the current investigation may explain the observed decreased efficacy. This metastatic pancreatic cancer model reflects the devastating nature of pancreatic cancer with mice becoming moribund on average of 19 days after tumor injection demonstrating tumor burden completely replacing the liver. 25 This development of tumor burden reflects the rapid decline in health we observe in the mice as tumors progress. Although the combined treatment only modestly prolonged survival compared with individual treatment arms, survival time was almost doubled relative to the control group. It should be noted that the treatment in the studies described here was only for 4 weeks. Based on the observation that minimal or no tumor burden was evident in the mice treated with the combination with SGT-53 and gemcitabine by day 19, continued treatment has the potential to increase survival even further.
This investigation highlights the potential of systemically delivered gene therapy using a Tf receptor-targeted nanoparticle to enhance current therapeutic strategies in pancreatic cancer. The ability to deliver effectively tumor-targeted nanoparticles as demonstrated in our investigations may open the door for novel nanoparticle-based therapeutic applications in pancreatic cancer. Furthermore, a Phase I clinical trial in patients with advanced solid tumors was recently completed with a single agent SGT-53. The single agent was well tolerated, with the majority of patients demonstrating stable disease following treatment. The promising Phase I results combined with our preclinical data support the development of Phase Ib/II clinical trials in pancreatic cancer evaluating the combination therapy.
CONCLUSION
Wtp53 gene therapy via the systemically administered Tf receptortargeted nanocomplex can effectively target pancreatic cancer tumors and enhance gemcitabine chemotherapy. Our findings support the development of pancreatic cancer Phase Ib/II clinical trials using this combined therapeutic strategy as a new potentially more effective treatment for pancreatic cancer.
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